FutureCure Health completes Rs 104 crore funding for vertigo care 

New Delhi: Vertigo and balance disorders impact nearly six crore people in India. These patients are often misdiagnosed or treated with symptom-suppressing medication rather than specific therapy for the underlying disease.

Addressing this critical gap, FutureCure Health Private Limited, a healthcare technology company focused on super-speciality care, has completed a Rs 104 crore funding round to expand access to the diagnosis and treatment of vertigo.

The investment was led by Carnelian Asset Management LLP, with participation from other marquee investors. The fundraising follows an earlier USD 4 million round in 2022 backed by Kotak Alternate Asset Management, RVCF Ventures, and Unicorn India Ventures.

FutureCure runs NeuroEquilibrium, its wholly owned subsidiary and the world’s largest chain of vertigo and dizziness diagnostic and rehabilitation clinics. Unlike conventional approaches, NeuroEquilibrium focuses on identifying the root cause of vertigo, whether arising from the inner ear, the brain, or the balance pathways, thus enabling targeted treatment rather than temporary relief. Working closely with hospitals, ENT clinics, and neurology centres, NeuroEquilibrium operates over 300 clinics in India and in 16 other countries and has enabled diagnosis and treatment for over 150,000 patients, significantly improving long-term outcomes.

Rajneesh Bhandari, Founder, FutureCure Health, said, “This funding has reinforced our conviction that globally relevant healthcare technologies can be built in India. As we scale NeuroEquilibrium across hospitals in India and globally and expand into chronic lifestyle diseases such as migraine and diabetes, our focus is on using technology to bridge the shortage of specialist doctors. Precise, scalable diagnostics can democratise super-speciality healthcare and act as a true force multiplier for better outcomes.” 

Dr. Anita Bhandari, Founder, FutureCure Health, added, “Vertigo/dizziness is often misdiagnosed, leaving patients untreated for years. Our work with 150,000+ patients proves that accurate diagnosis changes outcomes. This funding will help us take specialised vertigo care global.”